Exhibit 99.2
![LOGO](https://capedge.com/proxy/F-1/0001193125-20-307203/g85506dsp0015.jpg)
![LOGO](https://capedge.com/proxy/F-1/0001193125-20-307203/g85506g1112132659696.jpg)
December 1, 2020
To: Burning Rock Biotech Limited
601, 6/F, Building 3, Standard Industrial Unit 2
No. 7, Luoxuan 4th Road,
International Bio Island, Guangzhou, 510005
People’s Republic of China
Dear Sirs or Madams,
We are qualified lawyers of the People’s Republic of China (the “PRC” or “China”, for the purpose of this opinion only, the PRC shall not include the Hong Kong Special Administrative Region, the Macau Special Administrative Region and Taiwan) and as such are qualified to issue this opinion on the laws and regulations of the PRC effective as of the date hereof.
We act as the PRC counsel to Burning Rock Biotech Limited (the “Company”), a company incorporated under the laws of the Cayman Islands, in connection with (i) the proposed public offering of certain number of American depositary shares (the “Offered ADSs”), each Offered ADS representing certain number of ordinary shares of the Company (the “Ordinary Shares”), by the selling shareholders as set forth in the Company’s registration statement on Form F-1, including all amendments or supplements thereto (the “Registration Statement”), filed by the Company with the Securities and Exchange Commission (“SEC”) under the U.S. Securities Act of 1933 (as amended) in relation to the Offering, and (ii) the Company’s proposed listing of the Offered ADSs on the Nasdaq Global Market (collectively, the “Offering”).